
<DOC>
<DOCNO>WT03-B24-184</DOCNO>
<DOCOLDNO>IA064-000378-B002-228</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/Companies/ipi.html 206.86.52.80 19970112095258 text/html 7679
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 09:52:54 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 7497
Last-modified: Tue, 01 Oct 1996 18:08:10 GMT
</DOCHDR>
<HTML><HEAD><TITLE>Interneuron Pharmaceuticals, Inc.</TITLE></HEAD>
<BODY  BGCOLOR=#FFFFFF>
<IMG  Align=Middle SRC="../Graphics/ipi.gif"><H1>Interneuron Pharmaceuticals, Inc.</H1>
<H3>Corporate Profile</H3>
<A HREF = "ipijp.html"><IMG  Align=Middle SRC="../Graphics/japanese.gif"></A> <A HREF = "ipijp.html">Japanese Translation</A>
<HR>

99 Hayden Avenue MA 02173<BR>
Telephone +1-617-861-8444<BR>
Fax +1-617-861-3830<P><BR>

<B>Company officers / titles:</B><BR>
<UL><LI> Glenn L. Cooper, M.D., President & CEO<BR>
<LI> Mark S. Butler, EVP, Chief Administrative Officer, General Counsel<BR>
<LI> Bobby W. Sandage, Jr. Ph.D., EVP, Research & Development, Chief Science Officer<BR>
<LI> Thomas F. Farb, EVP, Finance and Chief Financial Officer<BR>
<LI> Brian R. Anderson, SVP, Marketing and Commercial Development<BR>
<LI> Takashi Kiyoizumi, M.D., Ph.D., VP, Business Development and Strategic Planing<BR>
<LI> Richard E. Gammans, Ph.D., VP, Clinical Research<BR>
<LI> William B. Boni, VP, Corporate Communications<BR>
<LI> Tessa W. Cooper, VP, Human Resources<BR>
<LI> Dale Ritter, VP and Corporate Controller<BR>
<LI> Sonja Loar, Pharm.D., VP, Regulatory & Scientific Affairs
</UL>

<B>Employees:</B> approximately 65, 6 PhDs, 1 MD, 1 MD/PhD, 1 JD<P>

<B>Facilities:</B> 20,000 sq. feet<P>

<B>Company Overview:</B><BR>
Interneuron Pharmaceuticals, Inc. is developing an extensive pipeline of pharmaceutical and biotechnology-based products. The company's programs target central nervous system disorders, including obesity, stroke, anxiety, insomnia, and Parkinson's disease.
Earlier stage core technologies with broad potential therapeutic applications are the focus of two majority-owned subsidiaries.  These include Progenitor, Inc., which is developing gene and cellular therapies based upon the potential of novel, early stem cells, and Transcell Technologies, Inc., which is developing drug transport and oligosaccharide synthesis technologies. Interneuron stock is listed in NASDAQ under IPIC.

<P>A third subsidiary, Intercardia, Inc., is developing cardiopulmonary products.  Intercardia's lead product, bucindolol, is in Phase III clinical testing for the treatment of congestive heart failure sponsored by the National Institutes of Health and Veterans Administration.  Intercardia completed its initial public offering in February, 1996 and its stock is currently traded in NASDAQ under ITRC.</P>

<P>The newest subsidiary of Interneuron is InterNutria, Inc.  InterNutria's focus is nutritional approaches to behavioral modification and the management of conditions including premenstrual syndrome (PMS), and athletic performance.
</P>

<B>Interneuron Program Overview:</B><P>
<TABLE BORDER =6>
<th>Program</th><th>	Disease Targets</th><th>Stage of Development</th><tr>
<td>Redux</td><td>Obesity</td><td>Launched</td><tr>

<td>Bucindolol</td><td>Congestive Heart Failure</td><td>Phase III</td><tr>

<td>Citicoline</td><td>Stroke</td><td>Phase III</td><tr>

<td>Pagoclone</td><td>Anxiety/panic disorders</td><td>Phase II/III to begin fall 1996</td><tr>

<td>Dihydrexidine</td><td>Parkinson's disease</td><td>Phase I</td><tr>

<td>Melatonin analog (IP 100-9) </td><td> Insomnia</td><td>Pre-IND</td><tr>

<td>Melzone</td><td>Insomnia</td><td>Pre-launch as a dietary supplement</td>
</TABLE><P><BR>

<B>Investors:</B><BR>
Interneuron was founded in 1988 by Lindsay A. Rosenwald, M.D., current Chairman of the Castle Group in New York, and Richard J. Wurtman, M.D., Professor of Neuroscience at MIT.   Interneuron went public in March 1990 and has raised approximately $196 million through public offerings, warrant exercises and private placements.<P><BR>

<B>Business Strategy and Corporate Partnering Opportunities:</B><BR>
<I>Key elements in Interneuron's business strategy include:</I><P>

<UL><LI> In-licensing clinical and late pre-clinical stage compounds with defined pathways to the clinic and to market.

<LI> Developing products and leading-edge technologies with broad applications and large, unsatisfied markets.

<LI> Establishing corporate marketing partnerships that will help ensure penetration of target markets as rapidly as possible.

<LI> Creating technological synergies among its companies.
</UL><P><BR>

<B>Scientific Advisory Board:</B><P>
Richard J. Wurtman, M.D., Chairman<BR>
Professor of Neuroscience and Director, Clinical Research Center<BR>
Massachusetts Institute of Technology<P>

Julius Axelrod, Ph.D.<BR>
Nobel Laureate<BR>
Guest Researcher, Laboratory of Cell Biology<BR>
National Institute of Mental Health<P>

Jan K. Blusztajn, Ph.D.<BR>
Assistant Professor<BR>
Boston University School of Medicine<P>

Thomas Chase, M.D.<BR>
Chief, Experimental Therapeutics Branch<BR>
National Institute of Neurological Disorders and Stroke<P>

John Growdon, M.D.<BR>
Associate Professor of Neurology<BR>
Harvard Medical School<P>

Israel Hanin, Ph.D.<BR>
Professor and Chairman<BR>
Department of Pharmacology and Experimental Therapeutics<BR>
Loyola University<P>

Bartley Hoebel, Ph.D.<BR>
Professor of Psychology<BR>
Princeton University<P>

Marvin E. Jaffe, M.D.<BR>
Former President<BR>
R.W. Johnson Pharmaceutical Research Institute<P>

Donald Jenden, M.D., Ph.D.<BR>
Professor of Pharmacology<BR>
UCLA Medical School<P>

Zaven Khachaturian, Ph.D.<BR>
Associate Director of Neuroscience and Neuropsychology<BR>
National Institute on Aging<P>

Donald F. Klein, M.D.<BR>
Professor of Psychiatry<BR>
Columbia University College of Physicians and Surgeons<P>

Steven Younkin, M.D., Ph.D.<BR>
Professor of Pathology and Pharmacology<BR>
Case Western Reserve University School of Medicine<P>

Judith J. Wurtman, Ph.D.<BR>
Research Scientist<BR>
Massachusetts Institute of Technology<P><BR>

<B>Board of Directors:</B><P>
Lindsay A. Rosenwald, M.D.<BR>
Chairman<BR>
The Castle Group Ltd.<BR>
Paramount Capital, Inc.<P>

Glenn L. Cooper, M.D.<BR>
President and Chief Executive Officer<BR>
Interneuron Pharmaceuticals, Inc.<P>

Harry J. Gray<BR>
President<BR>
Harry Gray Associates<P>

The Honorable Alexander M. Haig, Jr.<BR>
Former United States Secretary of State<BR>
Chairman<BR>
Worldwide Associates, Inc.<P>

Peter Barton Hutt<BR>
Partner, Covington and Burling<BR>
Former Chief Counsel, United States Food and Drug Association<P>

Malcolm Morville, Ph.D.<BR>
President and Chief Executive Officer<BR>
Phytera, Inc.<P>

Robert K. Mueller<BR>
Director, Arthur D. Little, Ltd.<P>

Lee J. Schroeder<BR>
President<BR>
Lee Schroeder Associates, Inc.<P>

David B. Sharrock<BR>
Former Executive Vice President and Chief Operating Officer<BR>
Marion Merrell Dow Inc.<BR>
Director, Marion Merrell Dow Inc.<P>

Richard J. Wurtman, M.D.<BR>
Professor of Neuroscience and Director, Clinical Research Center<BR>
Massachusetts Institute of Technology<P>

<A HREF = "http://www.sosei.com/"><IMG  Align=Middle SRC="../Graphics/home_button.gif"></A><A HREF = "http://www.sosei.com/">  Home Page</A><P>
<HR></BODY>
<ADDRESS><FONT SIZE=3>
Updated October 1, 1996.
Copyright &copy; 1995 <A HREF = "http://www.genweb.com/">GenWeb</A>.
All rights reserved.</FONT></ADDRESS>

<!-- INFORMATION ABOUT THE CONTACT PERSON FILLING OUT THIS FORM
Date: August 18, 1995

Name: Takashi Kiyoizumi, M.D., Ph.D.
Title: Vice President, Business Development & Strategic Planning
Business Address: 99 Hayden Avenue, Lexington, MA 02173
State: Massachusetts
Zip Code: 02173
Telephone Number: +1-617-861-8444
Fax Number: +1-617-861-3830
E-mail address: takak@halcyon.com -->
</HTML>

</BODY>
</HTML>
</DOC>